文摘
摘要目的:调查协会联合血清神经丝轻链(sNfL)和视网膜光相干断层扫描(OCT)测量与未来患者的疾病活动早期的多发性硬化症(MS)。
背景:增加sNfL水平和减少视网膜层厚度都单独被证明是有前途的生物标志物反映neuroaxonal损伤。
设计/方法:我们分析sNfL 10月由单分子阵列技术和执行测量78名临床孤立综合征患者的前瞻性群组和早期复发汇款女士用中位数(四分位范围)23.9(23.3 - -24.7)个月的随访。患者分为异常或正常sNfL水平,定义为sNfL≥/ < 80 age-corrected参考价值。同样,患者按平均分组分成薄或厚神经节细胞和内网状层(GCIPL),视神经盘旁视网膜神经纤维层和内部核层non-optic神经炎的眼睛。结果参数没有违反疾病活动的证据(NEDA-3)标准或其组件。
结果:异常患者基线sNfL违反NEDA-3有更高的风险(风险比(人力资源)(95%置信区间)= 2.28 (1.27 - -4.09),p = 0.006)和发展中一个新的大脑病变(HR = 2.47 (1.30 - -4.69), p = 0.006),但不是一个新的复发(HR = 2.21 (0.97 - -5.03), p = 0.058)。sNfL异常和薄GCIPL患者有更高的风险NEDA-3违反(HR = 3.61 (1.77 - -7.36), p = 4.2)的军医,新的大脑病变(HR = 3.19 (1.51 - -6.76), p = 0.002),和新的复发(HR = 5.38 (1.61 - -17.98), p = 0.006)比异常患者sNfL孤单。
结论:女士早期,患者存在异常sNfL和薄GCIPL未来风险因素越来越多的疾病活动比单独的每个参数。
披露:林先生没有披露。Vitkova女士没有披露。Asseyer博士已经收到个人补偿的范围0 - 499美元与Alexion担任议长。Asseyer博士已经收到个人补偿的范围为0 - 499美元作为演讲者与罗氏制药公司。Asseyer博士已经收到个人补偿的范围0 - 499美元与拜耳公司作为一个演讲者。女士Martorell Serra没有披露。Motamedi先生没有披露。Ditzhaus博士没有披露。帕斯卡Benkert没有披露。Kuhle博士没有披露。 Judith Bellmann-Strobl, MD has nothing to disclose. Dr. Ruprecht has received research support from European Union (821283-2). Dr. Ruprecht has received research support from Merck Serono. Dr. Ruprecht has received research support from Stiftung Charite. Dr. Ruprecht has received research support from Arthur Arnstein Foundation. Dr. Ruprecht has received publishing royalties from a publication relating to health care. The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe PC (MTPC). The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aarhus University. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Paul has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CELGENE. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ACRELION. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viela Bio. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizter. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Hanna Zimmermann has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis and Bayer. The institution of Hanna Zimmermann has received research support from Novartis.
